Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1303430 | 0.80 | SYK (0.36) | KDM4EALDH1A1POLB | |
| SCHEMBL21914981 | 0.77 | ALDH1A1 (0.41) | KDM4EALDH1A1POLBBCAT1GAA | |
| SCHEMBL24608334 | 0.72 | HCAR2 (0.43) | KDM4EALDH1A1POLBBCAT1 | |
| SCHEMBL19814227 | 0.69 | AR (0.42) | KDM4EALDH1A1POLBBCAT1 | |
| SCHEMBL21811571 | 0.69 | KDM4E (0.37) | KDM4EALDH1A1POLB | |
| SCHEMBL29584921 | 0.68 | ALDH1A1 (0.39) | KDM4EALDH1A1POLBBCAT1 | |
| SCHEMBL14303299 | 0.68 | POLB (0.39) | KDM4EALDH1A1POLBBCAT1 | |
| SCHEMBL24423786 | 0.68 | ALDH1A1 (0.39) | KDM4EALDH1A1POLBBCAT1 | |
| SCHEMBL1630093 | 0.68 | ALDH1A1 (0.44) | KDM4EALDH1A1POLBBCAT1GAA | |
| SCHEMBL360864 | 0.68 | ALDH1A1 (0.44) | KDM4EALDH1A1POLBBCAT1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299110-B2 | 2-(2-hydroxybiphenyl-3-yl)-1H-benzoimidazole-5-carboxamidine derivatives as factor VIIa inhibitors | PHARMACYCLICS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20110269806-A1 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS | PHARMACYCLICS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269806-A1 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS | F13B, HABP2, F7 | KDM4E 561/4885ALDH1A1 2997/4885POLB 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.